Critical Review: Positron (POSC) and Its Peers

Positron (OTCMKTS:POSC) is one of 78 public companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Positron to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and price targets for Positron and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	N/A
Positron Competitors	287	826	2136	109	2.62

As a group, “Electromedical equipment” companies have a potential upside of 2,878.06%. Given Positron’s competitors higher probable upside, analysts plainly believe Positron has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Positron and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-12.13
Positron Competitors	$970.73 million	$79.50 million	9.84

Positron’s competitors have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Positron and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-299.08%	-83.97%	-27.60%

Risk & Volatility

Positron has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500.

Summary

Positron competitors beat Positron on 8 of the 10 factors compared.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.